Literature DB >> 20227546

Cost-benefit analysis of state- and hospital-funded postpartum intrauterine contraception at a university hospital for recent immigrants to the United States.

Maria Isabel Rodriguez1, Aaron B Caughey, Alison Edelman, Philip D Darney, Diana Greene Foster.   

Abstract

OBJECTIVE: To examine the hospital and state costs of offering the option of a postpartum intrauterine device (IUD) to an underinsured population of recent immigrants to the United States with Emergency Medicaid (EM) insurance coverage only. STUDY
DESIGN: This study is a retrospective cohort study comparing the costs of offering a reversible long-acting method of contraception (IUD) postpartum to women with EM and the current policy of covering the obstetrical delivery only. A cost-benefit analysis from the perspective of both the hospital and the state was conducted. A database of EM obstetrical patients from 2002 to 2006 was created from hospital billing records to calculate mean pregnancy costs and revenue, as well as the probability of repeat pregnancy and pregnancy outcome. Probability of IUD uptake and continuation was obtained from hospital records and the literature.
RESULTS: A postpartum IUD program is not cost beneficial from the hospital's perspective, losing 70 cents per dollar spent on the program. However, the state government would save $2.94 for every dollar spent on a state-financed IUD program.
CONCLUSION: Considering only the direct costs associated with a repeat pregnancy, a program offering the option of postpartum IUD placement to underinsured women would significantly reduce state expenditures on subsequent pregnancies. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 20227546     DOI: 10.1016/j.contraception.2009.11.002

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  8 in total

1.  Immediate postpartum long-acting reversible contraception: the time is now.

Authors:  Michelle Moniz; Tammy Chang; Michele Heisler; Vanessa K Dalton
Journal:  Contraception       Date:  2016-11-29       Impact factor: 3.375

2.  Global fee prohibits postpartum provision of the most effective reversible contraceptives.

Authors:  Abigail R A Aiken; Mitchell D Creinin; Andrew M Kaunitz; Anita L Nelson; James Trussell
Journal:  Contraception       Date:  2014-08-07       Impact factor: 3.375

3.  Immediate Postpartum Contraception: A Survey Needs Assessment of a National Sample of Midwives.

Authors:  Michelle H Moniz; Lee Roosevelt; Halley P Crissman; Emily K Kobernik; Vanessa K Dalton; Michele H Heisler; Lisa Kane Low
Journal:  J Midwifery Womens Health       Date:  2017-09-07       Impact factor: 2.388

4.  Intrauterine Device Placement During Cesarean Delivery and Continued Use 6 Months Postpartum: A Randomized Controlled Trial.

Authors:  Erika E Levi; Gretchen S Stuart; Matthew L Zerden; Joanne M Garrett; Amy G Bryant
Journal:  Obstet Gynecol       Date:  2015-07       Impact factor: 7.661

5.  Development of a pharmacoeconomic registry: an example using hormonal contraceptives.

Authors:  Annesha White; Meenakshi Srinivasan; La Marcus Wingate; Samuel Peasah; Marc Fleming
Journal:  Health Econ Rev       Date:  2021-03-20

6.  Analysis of Contraceptive Use Among Immigrant Women Following Expansion of Medicaid Coverage for Postpartum Care.

Authors:  Maria I Rodriguez; Megan Skye; Stephan Lindner; Aaron B Caughey; Ana Lopez-DeFede; Blair G Darney; K John McConnell
Journal:  JAMA Netw Open       Date:  2021-12-01

7.  The Influence of Social Determinants of Health on the Provision of Postpartum Contraceptives in Medicaid.

Authors:  Irene Nsiah; Nidhi Vij Mali; Marie Barnard; Swarnali Goswami; Christy Lyle; Sujith Ramachandran
Journal:  Healthcare (Basel)       Date:  2022-02-03

8.  Immediate Postpartum IUD Training Within a Regional Network of Family Medicine Residencies.

Authors:  Ying Zhang; Sonali Sheth; Amanda K H Weidner; Patricia Egwuatu; Lauren Webb; Grace Shih
Journal:  PRiMER       Date:  2021-07-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.